Skip to main content
Boryung Corporation logo

Boryung Corporation — Investor Relations & Filings

Ticker · 003850 ISIN · KR7003850005 KO Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2026-02-23 Notice of Dividend Amou…
Country KR South Korea
Listing KO 003850

About Boryung Corporation

https://pharm.boryung.co.kr/eng/index.do

Boryung Corporation is a fully integrated healthcare company founded in 1957. Its core business encompasses the research, development, manufacturing, and global commercialization of pharmaceutical products, with a significant presence in the cardiovascular therapeutic area. The company is distinguished by its pioneering 'Care in Space' (CIS) initiative, which focuses on developing healthcare solutions for humans in extreme environments and leveraging space for new research opportunities. In addition to its pharmaceutical operations, Boryung functions as a healthcare investment company, fostering innovation across the health sector. The company's diverse portfolio includes prescription drugs, over-the-counter products, and a pipeline aimed at addressing future medical needs.

Recent filings

Filing Released Lang Actions
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Boryung regarding a decision on cash dividends. It specifies the dividend amount per share, the dividend yield, the record date, and the expected payment date. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2026-02-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This document details the sale of shares by an executive (Lee Geun-jae) of Boryeong Corporation. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it tracks insider transactions by company management.
2026-02-19 Korean
[기재정정]연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is a formal regulatory filing titled 'Correction Report' (정정신고) regarding previously disclosed preliminary earnings (연결재무제표기준영업(잠정)실적). It provides a detailed comparison of financial figures before and after a correction necessitated by a legal ruling (1st instance court decision on drug price reduction). Since this is a direct update to financial performance metrics and not merely an announcement of a report's availability, it falls under the category of Earnings Release (ER) as it details the revised quarterly financial results. Q4 2025
2026-02-13 Korean
투자판단관련주요경영사항 (BR1018 임상3상 결과)
Legal Proceedings Report Classification · 95% confidence The document is a formal regulatory filing from Boryung, titled 'Investment Judgment Related Major Management Matters'. It details the results of a Phase 3 clinical trial for a new drug (BR1018). In the context of Korean corporate filings (KIND/KRX), this type of disclosure regarding clinical trial outcomes is classified as a regulatory filing (RNS) as it provides material information to investors regarding business operations and R&D progress, but does not fit into specific categories like financial reports or shareholder meeting materials.
2026-02-10 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Release' (영업(잠정)실적) for Boryung Corporation. It provides key financial highlights (revenue, operating profit, net income) for the 4th quarter of 2025 and the full year. It is a concise summary of financial performance, not a full annual report or a transcript, and it is explicitly labeled as a preliminary disclosure (공정공시). Therefore, it fits the definition of an Earnings Release (ER). Q4 2025
2026-02-02 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the resignation of an outside director (사외이사). It details the specific change in board composition, including the name of the director, the date of resignation, and the reason. This falls under the category of announcements regarding changes in the company's board of directors.
2026-01-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.